Bromexol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromexol

Property Description
Active ingredient Bromhexine Hydrochloride
Form Tablets, Oral Liquid (Syrup/Solution)
Pharmacological Class Mucolytic and Secretolytic Agent
Common Use Clearance of thick respiratory secretions
Origin Synthetic, derived from Vasicine

What is Bromexol and What Class of Medicine is It?

Bromexol is a trade name for a medicine containing the active ingredient Bromhexine, which is classified as a systemically active mucoactive agent. Its primary scientific designation is that of a mucolytic and secretolytic agent, aimed at the fundamental management of disorders involving the accumulation of thick, viscous mucus in the respiratory tract. Bromhexine's role is in liquefying and thinning bronchial secretions. Bromhexine belongs to the established class of medicines used for cough and cold preparations (Anatomical Therapeutic Chemical code R05CB02).


Composition, Origin, and Available Forms

The functional core of the medication is Bromhexine Hydrochloride, the chemically stable salt form of the active substance Bromhexine. This compound is synthetic, classified chemically as a phenylmethylamine derivative. Its structure is inspired by the quinazoline alkaloid vasicine, a natural compound derived from the Indian plant Adhatoda vasica. Bromexol is typically manufactured as a single-ingredient product and is primarily available in forms designed for oral administration, with common dosage form(s) including tablets and oral liquid (syrup or solution).


What is the General Purpose of This Type of Drug?

The general purpose of this type of drug is to facilitate the efficient clearance of respiratory secretions by altering the physical nature of mucus, thereby making a cough more effective. This is achieved through a dual mechanism involving the mucolytic action of thinning sticky phlegm and the secretolytic effect of increasing the volume of watery mucus. This combined mechanism helps manage respiratory congestion. Bromhexine is used to assist in the expectoration (coughing up) of tenacious sputum. The drug's primary function is to help clear difficult phlegm from the chest by modulating the rheology of the secretions.

What side effects are possible with Bromexol?

Possible side effects and safety information

Official regulatory documentation classifies the possible side effects of Bromhexine Hydrochloride (Bromexol) based on frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most frequently classified reactions are generally related to the digestive tract and are designated as uncommon in official prescribing information. Rare, but more serious, reactions concerning the immune system and skin have also been documented.

Classification Examples of Documented Adverse Reactions (SOC)
Uncommon Gastro-intestinal disorders (e.g., nausea, vomiting, diarrhoea, upper abdominal pain).
Rare Hypersensitivity reactions (e.g., rash, urticaria).
Not Known Anaphylactic reactions, anaphylactic shock, angioedema, bronchospasm, and severe cutaneous adverse reactions (SCARs).

Serious Adverse Reactions and Systemic Effects

The most serious, though rare, safety considerations involve Severe Cutaneous Adverse Reactions (SCARs), which include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Anaphylactic shock is also documented as a possible severe systemic reaction. Other systems associated with documented side effects include the Nervous system (e.g., headache, dizziness) and the Hepatic system (transient rise in serum aminotransferase values).

Safety Constraints and Population-Specific Considerations

Official labeling mandates caution for use in several specific situations. Use requires particular care in patients with severe hepatic (liver) or renal (kidney) impairment, as the clearance of the medicine may be reduced. Caution is also advised in individuals with a history of peptic ulceration or gastric ulceration. The product is generally not recommended for use during the first trimester of pregnancy or while breastfeeding. A specific constraint exists regarding patients who are unable to effectively expel mucus, due to the risk of accumulated secretions.

This information describes the medicine’s official safety classification, based on the framework used by government regulatory agencies.

Overdose and Emergency Response

The official regulatory profile for Bromexol (Bromhexine Hydrochloride) overdose indicates that no specific overdose symptoms have been reported in man. Manifestations following the ingestion of excessive amounts are generally consistent with the drug’s known adverse effects.

Documented presentations include gastrointestinal disturbances, such as Nausea, Vomiting, Diarrhoea, and Upper Abdominal Pain, along with systemic effects like Headache, Dizziness, and Sweating. Management of an overdose is formally defined as being symptomatic and supportive.

Regulatory documents confirm that no specific antidote is known for Bromhexine overdose.

When Urgent Medical Help Must Be Sought

The official regulatory basis for seeking urgent medical care is centered on severe, life-threatening outcomes. It is mandated to seek immediate medical attention if an excessive amount is ingested.

Immediate action is required if symptoms or signs of a severe systemic reaction occur, including Anaphylactic Shock or Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). If a progressive skin rash or any sign of a severe allergic reaction is observed, the official guidance requires that Bromexol treatment must be discontinued immediately, and medical advice must be sought. For suspected overdose cases, patients are instructed to immediately contact the Poisons Information Centre.

Therapeutic Uses of Bromexol

Easing Chest Congestion from Viscous Mucus

Bromexol is used in situations involving certain distressing symptoms associated with the lower respiratory tract, specifically when the cough is productive but the mucus is abnormally thick or sticky. The medication is used for the management of symptomatic chest congestion in situations where thick secretions are present. It is commonly used across conditions presenting with acute episodes of respiratory tract congestion, as well as in managing exacerbations of chronic conditions like chronic bronchitis, where thick phlegm is a feature.

Indications: The medicine is considered relevant for easing symptoms during episodes of acute bronchitis, chronic bronchitis exacerbations, influenza, and the common cold when significant, tenacious sputum is present.

Supporting a Productive and Effective Cough

The primary symptomatic benefit focuses on supporting impaired expectoration. Bromexol is relevant for easing challenging symptoms related to thick phlegm, and is commonly used to help with a cough that is difficult to make productive. This contributes to improved comfort during periods of heightened symptoms, assists with maintaining functional stability by reducing the overall symptom burden of stubborn chest congestion.

“The medication is applied in scenarios where additional management of discomfort is required due to the difficulty of clearing the chest.”


Quick Fact: Relief for Thick, Tenacious Phlegm The main role of Bromexol is to support the patient during episodes of thick secretions, which assists in making the resulting cough more effective and manageable.

Regulatory References

  1. Australian Therapeutic Goods Administration Monograph

Eligibility and Restrictions for Use

Eligibility for Bromexol (Bromhexine Hydrochloride)

Official regulatory information defines specific populations that are permitted, restricted, or prohibited from using Bromexol. This medicine is generally permitted for Adults and Adolescents (12 years and over). Use is restricted for Children aged 6 to 11 years, who should only use the medicine on the advice of a doctor or pharmacist.


Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to bromhexine or any component of the formulation. It is also contraindicated for children under 6 years of age. Tablet or liquid formulations may be contraindicated in patients with rare hereditary issues like galactose or fructose intolerance, depending on excipients.


Populations Requiring Caution or Restriction

Use requires caution in patients with severe hepatic impairment or severe renal impairment due to the potential for reduced drug clearance and metabolite accumulation. Individuals with a history of gastric or peptic ulceration should also use Bromexol with caution.

For pregnant women, use is generally not recommended, particularly during the first trimester. Use is also not recommended for breastfeeding mothers, as the excretion of bromhexine into breast milk is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bromexol (Bromhexine Hydrochloride) has a regulatory interaction profile characterized primarily by two pharmacodynamic patterns and specific pharmacokinetic considerations as outlined in official government prescribing information.


Documented Interaction Patterns

Interaction Type Interacting Substance(s) Official Regulatory Outcome
Pharmacodynamic Conflict Cough suppressants (Antitussives) Co-administration is advised against due to the potential for accumulated secretions in the airways.
Pharmacodynamic Enhancement Amoxicillin, Erythromycin, Oxytetracycline Increases the concentration of these antibiotics in bronchopulmonary secretions.
Pharmacokinetic Exposure Food Intake Increases Bromhexine plasma concentrations (C max).

Clearance and Special Populations

Official labels note that the overall potential for clinically unfavorable drug-drug interactions is low. However, a key pharmacokinetic consideration is that the clearance of Bromhexine or its active metabolites may be reduced in patients with severe hepatic or renal impairment. This reduction in clearance could lead to increased systemic exposure of the medicine. Formal studies for co-administration with substances like oral anticoagulants or digoxin have not shown clinically relevant interactions.

Mechanism of Action

Molecular Breakdown of Secretions (Mucolysis)

This domain covers the drug's primary action on the structure of mucus. Bromhexine increases the activity of hydrolytic lysosomal enzymes within bronchial glands, which chemically break down the long, sticky acid mucopolysaccharide fibers in the mucus. This molecular modification results in secretions with a measurably lower viscosity and tenacity.


Quantitative Change and Surfactant Action (Secretolysis and Fluid Dynamics)

Bromhexine exhibits a dual-action mechanism by simultaneously stimulating the production of a thinner, more watery serous fluid (secretolysis) and increasing the release of pulmonary surfactant by alveolar cells. The increased fluid contributes to the hydration of the mucus, while the surfactant reduces the adhesive forces between the secretion and the airway lining.


Enhancement of Mucociliary Clearance

The combined effect of molecular breakdown, increased watery fluid, and reduced adhesion results in secretions with modified rheological properties. This physiological change facilitates ciliary function, thereby increasing the efficiency of the mucociliary clearance (MCC) system, which transports material out of the respiratory tract.

Dosage and Administration Information

Administration Guidelines for Bromexol

Bromexol (Bromhexine Hydrochloride) is a medicine used according to standardized administration protocols. The primary route of administration is oral, available in both tablet form and an oral solution. A specialized intravenous (IV) injection formulation is also officially listed for use within specific, supervised clinical settings.


Standardized Regimen and Usage Pattern

The official use protocol is designed for short-term administration. The standard adult dose (for individuals aged 12 years and older) is typically 8 mg per administration. This dosage is generally scheduled to be taken three times daily (TID). Some guidelines permit increasing the dose up to 16 mg per administration for initial intensive treatment; however, the total course of treatment should not exceed seven consecutive days unless re-evaluated by a healthcare professional.


Contextual Instructions

The medicine may be administered with or without food. For the oral liquid form, precise volumetric delivery is mandatory, requiring the use of the calibrated measuring device provided with the product to ensure dose accuracy. Pediatric dosing is strictly age-banded and lower than the adult regimen, with use in children under the age of two typically requiring explicit medical supervision. Official guidance advises against attempting to compensate for a missed dose by doubling the subsequent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bromexol

Evidence for Mucus Clearance in Acute and Chronic Respiratory Conditions

Research exploring Bromexol (Bromhexine) has primarily been conducted using Randomized Controlled Trials (RCTs). These studies were applied in examining adult cohorts experiencing acute bronchitis and exacerbations of chronic bronchitis, specifically where the cough may be hindered by thick, viscous phlegm.

The primary goal of these studies was to observe what effects the agent had on the physical characteristics of sputum. Studies reported that populations receiving the agent were observed to have patterns related to a measured decrease in sputum viscosity and an increase in sputum volume during the study period. This research provides context regarding the measured change in the physical properties of the secretions themselves.

The findings were mixed across all outcomes. While the changes in the physical properties of secretions were often noted, some studies examining systemic or functional imbalance reported that specific changes in overall measures, such as breathing capacity, were not recorded when compared to a placebo.


Outcomes Measured in Clinical Trials and Research Gaps

Researchers monitored outcomes related to physical discomfort, such as the time it took for the cough to resolve and the time required for specific pathological sounds (rales) in the chest to disappear. Research examining temporary physiological imbalance in some studies recorded patterns where the duration for these specific pulmonary symptoms was shorter in observed populations. The research contributes to insight into short-term changes, as observation periods typically focused on temporary physiological imbalance and lasted only for the acute symptomatic phase.

Evidence quality varies across studies, and it is noted in scientific literature that data are still emerging, particularly regarding definitive conclusions on broad clinical effectiveness. Key limitations noted include the recognized need for larger, more rigorously designed trials.

Comparative evidence is lacking for specific, vulnerable groups, meaning there is limited information on how outcomes may differ for children, older adults, or individuals with certain comorbid conditions. Information regarding long-term effects is limited, as the evidence base does not monitor functional imbalance over extended time periods.

Key Studies & References

  1. Over-the-counter (OTC) medicine monograph: Bromhexine hydrochloride (Australia TGA)
  2. [Bromhexine for acute bronchitis: a systematic review]

Frequently Asked Questions (FAQ)

Common questions about Bromexol (FAQ)


Q: Is Bromexol the same as other similar-sounding medicines?

A: Bromexol is a trade name for a medicine containing the active ingredient Bromhexine Hydrochloride. While it belongs to a specific pharmacological class (mucolytics), other medicines that sound similar usually contain different active ingredients. According to official classifications, its formulation is distinct from these other products.


Q: How quickly can someone expect Bromexol to start working?

A: Studies on Bromexol’s mechanism of action indicate that its effect on mucus consistency is described as beginning shortly after the active ingredient enters the system. The medicine works by chemically breaking down thick mucus. The time it takes to notice a perceived effect on a cough or secretions may vary.


Q: How long does the effect of a single dose of Bromexol last?

A: Official administration guidelines often recommend that Bromexol is taken multiple times per day, such as three times daily. This scheduling describes the frequency at which the medicine is typically administered in official regimens.


Q: Does Bromexol cause drowsiness or make you tired?

A: Official regulatory documents list side effects related to the nervous system, such as dizziness and headache, which are usually classified as uncommon. Drowsiness or fatigue are not typically listed as frequent adverse reactions. Regulatory warnings indicate that patients who experience these effects may be advised against driving or operating machinery.


Q: Are there any common foods or drinks that interact with Bromexol?

A: Official regulatory information typically states that Bromexol can be taken with or without food. There are no widely documented interactions with specific foods or drinks that necessitate a change in diet while using the medicine.


Q: Can Bromexol affect sleep patterns?

A: The medicine is not generally classified as having a sedating or stimulating effect. While effects on sleep are not commonly listed as a direct side effect, some documented uncommon effects, such as nervousness or gastrointestinal discomfort, could potentially interfere with sleep.


Q: Is Bromexol appropriate for use in older adults?

A: Regulatory guidance permits the use of Bromexol in Adults, which includes older individuals. However, the official product information advises caution for all patients, including older adults, who have severe hepatic (liver) or renal (kidney) impairment, due to the potential for the medicine's clearance to be reduced.


Q: Do you need a prescription to get Bromexol?

A: The regulatory status of Bromexol (Bromhexine) can vary by location. In many regions, the medicine is registered as an over-the-counter (OTC) medicine, available without a prescription. Specific strengths, liquid forms, or combination products may still require a prescription depending on local law.


Q: Can Bromexol be used for long periods?

A: The official use protocol for Bromexol is designed for short-term administration. Regulatory documents typically advise that the course of treatment should not exceed a specific time frame, often around seven days, unless the patient has been re-evaluated by a healthcare professional.


Q: Will taking Bromexol affect my ability to drive or operate machinery?

A: Official information advises caution because the medicine may rarely cause side effects such as dizziness or headache. If a patient experiences these nervous system effects during treatment, they may be advised against driving or operating complex machinery.


Q: Is it normal to feel a mild stomach upset when starting Bromexol?

A: Official documentation lists gastro-intestinal disorders, such as nausea, vomiting, or upper abdominal pain, as uncommon side effects of Bromexol. The severity of these uncommon reactions is not precisely quantified in core regulatory documents.


Q: If I stop taking Bromexol suddenly, will I have withdrawal effects?

A: Regulatory-related information indicates that Bromhexine is not habit-forming. Therefore, abrupt discontinuation of the medicine is not associated with classic drug withdrawal symptoms. However, the symptoms for which the medicine was being taken may return.


Q: Is Bromexol commonly prescribed in different countries?

A: Yes. Regulatory documents and product registrations from health authorities across different continents confirm that Bromhexine (Bromexol) is a widely authorized and marketed medicine globally. It is commonly used as a mucolytic agent in many countries across Europe, Asia, and other regions.


Q: Are there any specific laboratory tests that can be affected by Bromexol?

A: Official safety documentation notes possible transient rises in serum aminotransferase values, which are a measure of liver enzymes commonly monitored in laboratory tests. Patients with severe liver impairment are specifically identified as requiring caution and monitoring.


Q: Does Bromexol have a high risk of interaction with blood pressure medicines?

A: Official labels generally state that the overall potential for clinically unfavorable drug-drug interactions with Bromexol is low. There are no specific, widely documented, and clinically relevant interactions listed between Bromhexine and most common classes of blood pressure medications.


Q: Does Bromexol contain gluten, lactose, or common allergens?

A: The inclusion of specific ingredients like gluten or lactose depends on the exact formulation and manufacturer. Some tablet or liquid forms may contain lactose or fructose as inactive ingredients (excipients). Information regarding the presence of common allergens is located within the official product excipient list.


Q: How is the research on Bromexol usually conducted?

A: Research on the medicine has primarily utilized Randomized Controlled Trials (RCTs). These studies typically examine the drug's effect on populations with respiratory conditions, focusing on observed changes in the physical characteristics of sputum and the duration of specific pulmonary symptoms.


Q: What kind of benefits should I generally expect from Bromexol?

A: The primary expected outcome is the facilitation of the clearance of thick respiratory secretions. Bromexol is designed to reduce the viscosity (thickness) of mucus, which generally makes the cough more productive and makes it easier to expel phlegm from the chest.


Q: Is Bromexol appropriate for use in children?

A: Appropriateness is strictly age-dependent. Bromexol is typically contraindicated (must not be used) for children under 6 years of age. For children aged 6 to 11 years, use is restricted and is generally advised only under the guidance of a doctor or pharmacist.


Q: What are the signs of taking too much Bromexol?

A: Official documents discussing acute overdose state that symptoms may include vomiting, diarrhoea, and dizziness. Official guidance indicates that immediate medical attention is sought, with symptomatic treatment generally advised.


Q: Does taking Bromexol mean I am cured of the underlying condition?

A: No. Bromexol is classified as a mucolytic and secretolytic agent. Its function is to modify the physical properties of mucus to help clear respiratory secretions, which addresses a symptom, but it does not cure the underlying cause of the condition.


Q: Are there different strengths or forms of Bromexol available?

A: Yes. Bromexol is officially available in several dosage forms, including tablets, an oral liquid (syrup or solution), and, in specific clinical settings, a specialized intravenous injection formulation. Strengths vary based on the form and the recommended age group.


Q: Can Bromexol be taken with pain medication?

A: The overall potential for clinically unfavorable drug-drug interactions with Bromexol is generally stated to be low. There are no specific warnings or contraindications in regulatory documents for co-administration with common over-the-counter pain medications.


Q: What are the legal restrictions on selling Bromexol?

A: Sales restrictions are determined by the local regulatory body. In many regions, the medicine is available without a prescription (OTC) at pharmacies. However, depending on local regulations, specific dosages or forms may require a prescription.


Q: Does Bromexol have a generic version available?

A: Yes. Since the name Bromexol is a trade name for the active ingredient Bromhexine Hydrochloride, numerous other products containing the same active substance are registered and available globally as generics or other branded versions.


Q: Can Bromexol be taken on an empty stomach?

A: Official administration guidelines state that the medicine may be administered with or without food. This means the timing relative to meals does not generally affect the intended use of the medicine.


Q: Is it true that Bromexol is mainly for short-term use?

A: Yes. The official use protocol for Bromexol in respiratory conditions is designed for short-term administration. Regulatory documents advise against exceeding a typical treatment duration, such as seven days, without further medical guidance.


Q: Why do some people say Bromexol didn't work for them?

A: Research evidence indicates that findings have been mixed across all measured outcomes. While studies often noted measured changes in the physical properties of sputum (making it thinner), some trials reported that specific changes in overall systemic measures, such as breathing capacity, were not always recorded compared to a placebo.


Q: Is it okay to drink alcohol while taking Bromexol?

A: The official interaction profile of Bromexol addresses food and specific drug types, but there is no widely documented clinical interaction with alcohol that is mentioned in core regulatory documents. The absence of a specific warning does not constitute a recommendation regarding concurrent use.

How should Bromexol be stored and disposed of?

How to Store and Dispose of Bromexol (Bromhexine Hydrochloride)

Official regulations define strict conditions for storing Bromexol to ensure stability.

Storage Requirements

The product must be stored at a temperature not exceeding 30 C and, for liquid formulations, must be protected from light by keeping it in the original container or outer carton. Bromhexol must always be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired medicine must be disposed of in accordance with local requirements, such as returning it to a pharmacist. Regulatory instructions prohibit disposing of the product via wastewater or household waste to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromexol found in:

A-Z Index: